Survival, Quality of Life and Self-reported Outcomes of Elderly Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab (MK-3475) in the First Line Setting
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms PEBEL
- 25 Jul 2019 Planned primary completion date changed from 15 Jun 2019 to 15 Nov 2019.
- 31 Aug 2018 Biomarkers information updated
- 13 Mar 2018 Status changed from not yet recruiting to recruiting.